Summary

Persistence Market Research has recently published an in-depth analysis of the global urinary incontinence therapeutics market. This detailed report explores key market dynamics, including drivers, trends, opportunities, and challenges, providing a comprehensive overview of the market structure.

Key Insights:

• Urinary Incontinence Therapeutics Market Size (2024E): US$4.4 Bn
• Projected Market Value (2031F): US$5.8 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Urinary Incontinence Therapeutics Market - Report Scope:

Urinary incontinence therapeutics cover various treatments aimed at managing and alleviating urinary incontinence, a prevalent condition worldwide. These therapeutics include pharmacological treatments, surgical interventions, and non-pharmacological management strategies. The market serves hospitals, clinics, urology centers, and homecare settings, offering options such as anticholinergics, beta-3 adrenergic agonists, surgical devices, and pelvic floor muscle training.

Market Growth Drivers:

Several factors drive the global urinary incontinence therapeutics market, including the increasing prevalence of urinary incontinence among the elderly and growing awareness of treatment options. Advances in therapeutic technologies, such as minimally invasive surgical techniques and new pharmacological agents, are improving treatment efficacy and patient satisfaction. Additionally, the rise in lifestyle modifications, behavioral therapies, and healthcare spending is contributing to market growth.

Market Restraints:

Despite positive growth prospects, the market faces challenges such as high treatment costs, limited insurance coverage, and variability in patient responses. Expensive advanced surgical procedures and long-term pharmacological treatments can be barriers, especially in emerging economies with limited healthcare budgets. Regulatory hurdles and stringent approval processes for new therapies also impact market innovation and growth.

Market Opportunities:

Opportunities in the urinary incontinence therapeutics market are driven by ongoing R&D, demographic shifts, and evolving treatment paradigms. Innovations in drug formulations, such as extended-release and combination therapies, enhance patient compliance and outcomes. The integration of digital health technologies, including mobile health apps and telemedicine, improves patient access to treatment and follow-up care. Strategic partnerships, investment in clinical trials, and development of cost-effective solutions are key to seizing these opportunities and sustaining market growth.

Key Questions Answered in the Report:

• What are the main factors driving global market growth for urinary incontinence therapeutics?
• Which therapeutic types and treatment modalities are leading adoption across various healthcare settings?
• How are technological advancements reshaping the competitive landscape of the market?
• Who are the key players in the urinary incontinence therapeutics market, and what strategies are they using?
• What are the emerging trends and future prospects in this market?

Competitive Intelligence and Business Strategy:

Key players in the urinary incontinence therapeutics market, including Pfizer Inc., Astellas Pharma Inc., Allergan plc, and Medtronic plc, focus on innovation, product differentiation, and strategic collaborations. These companies invest in R&D to create advanced therapeutic solutions, including novel drugs and surgical devices, catering to diverse patient needs. Partnerships with healthcare providers, regulatory bodies, and research institutions enhance market access and promote technology adoption. Emphasis on clinical research, patient education, and personalized treatment approaches drives market growth and improves patient outcomes.

Key Companies Profiled:

• Pfizer Inc.
• Astellas Pharma Inc.
• Allergan plc
• Medtronic plc
• Boston Scientific Corporation
• Coloplast A/S
• Urovant Sciences Ltd.
• Santen Pharmaceutical Co., Ltd.
• Endo International plc
• Kaken Pharmaceutical Co., Ltd.

Urinary Incontinence Therapeutics Industry Segmentation

By Type
• Urge Incontinence
• Overflow Incontinence
• Stress Incontinence
• Functional Incontinence

By Drug Class
• Anticholinergics
• Beta-3 Adrenoceptor Agonists
• Alpha Blockers
• Estrogen
• Desmopressin
• Tricyclic Antidepressants

By End User
• Hospitals
• Retail Pharmacy
• Online Pharmacy

By Region
• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Urinary Incontinence Therapeutics Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Drug Type Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.3.1. List of End-user/Marketplaces
3.3.1.1. Retail
3.3.1.2. Audiology
3.3.1.3. E-Commerce
3.3.2. List of End User (Industry)
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
4.3. Urinary Incontinence Therapeutics Market Outlook: Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
4.3.3.1. Urge Incontinence
4.3.3.2. Overflow Incontinence
4.3.3.3. Stress Incontinence
4.3.3.4. Functional Incontinence
4.3.3.5. Other
4.4. Market Attractiveness Analysis: Type
4.5. Urinary Incontinence Therapeutics Market Outlook: Drug Class
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
4.5.3.1. Anticholinergics
4.5.3.2. Beta-3 Adrenoceptor Agonists
4.5.3.3. Alpha Blockers
4.5.3.4. Estrogen
4.5.3.5. Desmopressin
4.5.3.6. Tricyclic Antidepressants
4.5.3.7. Other
4.6. Market Attractiveness Analysis: Drug Class
4.7. Urinary Incontinence Therapeutics Market Outlook: End-user
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Bn) Analysis, By End-user, 2019-2023
4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
4.7.3.1. Hospitals
4.7.3.2. Retail Pharmacy
4.7.3.3. Online Pharmacy
4.8. Market Attractiveness Analysis: End-user
5. Urinary Incontinence Therapeutics Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.3.1. By Country
6.3.2. By Type
6.3.3. By Drug Class
6.3.4. By End-user
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.4.1. U.S.
6.4.2. Canada
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
6.5.1. Urge Incontinence
6.5.2. Overflow Incontinence
6.5.3. Stress Incontinence
6.5.4. Functional Incontinence
6.5.5. Other
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
6.6.1. Anticholinergics
6.6.2. Beta-3 Adrenoceptor Agonists
6.6.3. Alpha Blockers
6.6.4. Estrogen
6.6.5. Desmopressin
6.6.6. Tricyclic Antidepressants
6.6.7. Other
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
6.7.1. Hospitals
6.7.2. Retail Pharmacy
6.7.3. Online Pharmacy
6.8. Market Attractiveness Analysis
7. Europe Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.3.1. By Country
7.3.2. By Type
7.3.3. By Drug Class
7.3.4. By End-user
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Turkey
7.4.8. Rest of Europe
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
7.5.1. Urge Incontinence
7.5.2. Overflow Incontinence
7.5.3. Stress Incontinence
7.5.4. Functional Incontinence
7.5.5. Other
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
7.6.1. Anticholinergics
7.6.2. Beta-3 Adrenoceptor Agonists
7.6.3. Alpha Blockers
7.6.4. Estrogen
7.6.5. Desmopressin
7.6.6. Tricyclic Antidepressants
7.6.7. Other
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
7.7.1. Hospitals
7.7.2. Retail Pharmacy
7.7.3. Online Pharmacy
7.8. Market Attractiveness Analysis
8. East Asia Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.3.1. By Country
8.3.2. By Type
8.3.3. By Drug Class
8.3.4. By End-user
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
8.5.1. Urge Incontinence
8.5.2. Overflow Incontinence
8.5.3. Stress Incontinence
8.5.4. Functional Incontinence
8.5.5. Other
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
8.6.1. Anticholinergics
8.6.2. Beta-3 Adrenoceptor Agonists
8.6.3. Alpha Blockers
8.6.4. Estrogen
8.6.5. Desmopressin
8.6.6. Tricyclic Antidepressants
8.6.7. Other
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
8.7.1. Hospitals
8.7.2. Retail Pharmacy
8.7.3. Online Pharmacy
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.3.1. By Country
9.3.2. By Type
9.3.3. By Drug Class
9.3.4. By End-user
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.4.1. India
9.4.2. Southeast Asia
9.4.3. ANZ
9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
9.5.1. Urge Incontinence
9.5.2. Overflow Incontinence
9.5.3. Stress Incontinence
9.5.4. Functional Incontinence
9.5.5. Other
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
9.6.1. Anticholinergics
9.6.2. Beta-3 Adrenoceptor Agonists
9.6.3. Alpha Blockers
9.6.4. Estrogen
9.6.5. Desmopressin
9.6.6. Tricyclic Antidepressants
9.6.7. Other
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
9.7.1. Hospitals
9.7.2. Retail Pharmacy
9.7.3. Online Pharmacy
9.8. Market Attractiveness Analysis
10. Latin America Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.3.1. By Country
10.3.2. By Type
10.3.3. By Drug Class
10.3.4. By End-user
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
10.5.1. Urge Incontinence
10.5.2. Overflow Incontinence
10.5.3. Stress Incontinence
10.5.4. Functional Incontinence
10.5.5. Other
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
10.6.1. Anticholinergics
10.6.2. Beta-3 Adrenoceptor Agonists
10.6.3. Alpha Blockers
10.6.4. Estrogen
10.6.5. Desmopressin
10.6.6. Tricyclic Antidepressants
10.6.7. Other
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
10.7.1. Hospitals
10.7.2. Retail Pharmacy
10.7.3. Online Pharmacy
10.8. Market Attractiveness Analysis
11. Middle East & Africa Urinary Incontinence Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.3.1. By Country
11.3.2. By Type
11.3.3. By Drug Class
11.3.4. By End-user
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.4.1. GCC Countries
11.4.2. Egypt
11.4.3. South Africa
11.4.4. Northern Africa
11.4.5. Rest of Middle East & Africa
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
11.5.1. Urge Incontinence
11.5.2. Overflow Incontinence
11.5.3. Stress Incontinence
11.5.4. Functional Incontinence
11.5.5. Other
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
11.6.1. Anticholinergics
11.6.2. Beta-3 Adrenoceptor Agonists
11.6.3. Alpha Blockers
11.6.4. Estrogen
11.6.5. Desmopressin
11.6.6. Tricyclic Antidepressants
11.6.7. Other
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End-user, 2024-2031
11.7.1. Hospitals
11.7.2. Retail Pharmacy
11.7.3. Online Pharmacy
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Pfizer Inc
12.3.1.1. Overview
12.3.1.2. Segments and Type
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. AbbVie Inc.
12.3.3. Astellas Pharma Inc.
12.3.4. Johnson & Johnson
12.3.5. Viatris Inc.
12.3.6. Teva Pharmaceutical Industries Ltd.
12.3.7. Sanofi S.A.
12.3.8. GlaxoSmithKline plc
12.3.9. Boehringer Ingelheim Pharmaceuticals, Inc.
12.3.10. Bayer AG
12.3.11. Ferring Pharmaceuticals
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations